托伐普坦的国内外临床研究进展-江冬青

5．J．2005199592－594．6．J．200319755－56．7．J．2002153136－138．8．J．201016162－63．9．J．2008817－9．10．J．2006411264．11．J．2012126441－442．12．J．2009910144－145．2014－01－02··511400【】【】Ｒ591．1【】A【】1674－3296201403B－0176－03135～145mmol/L＜135mmol/L、、。、、、、、、SIADH。OtsukaPharmV22009519FDA、SIADHV2。。3～4mmol/L。。。AVP。。11．1EVEＲESTEVEＲEST1、2、、22003107－200623、35941339．9。、。、、2、。、。1、17。。Blair3EVEＲEST12516885641619。1．2UdelsonUdelsonLVEDV1LV。4。Udelson5、48181LVEF23%NYHAⅢPCWP18mmHg1mmHg=0．133kPa15、30、60mg3PCWP、3h·671·2014373ChinJofClinicalＲationalDrugUseMarch2014Vol.7No.3B。1．3Ferrer。5000、、6。1．4GheorghiadeGheorghiade7、、3411≥181159330、6090mg9∶00AMJVD、。1、10749～51。60d。24h60d、。31P0．02＜0.001＜0．001、、。Gheorghiade7ACTIV-CHF31930～90mg/d24hP＜0.00168。25430～60mg125P＜0．00170180%40%P＜0.058。＞135mmol/L≥10%10～60mg/d27d9。1．5PangPang10。22．11138++7d。1122～3d。2．21215、30、60120mg48h、、24hP＞0．05。15、30、60120mg24h。6～12h5．1～7．3mmol/L。320124MHＲA、、、。4＜800ml13、、1～5h≤6mmol/L6～12h≤8mmol/L14。2012430FDA。1400ADPKD、3、。90mg30mg60mg3。FDA、、、。、。。。1GheorghiadeMKonstamMABurnettJCJretal．Short-termclinical·771·2014373ChinJofClinicalＲationalDrugUseMarch2014Vol.7No.3Beffectsoftolvaptananoralvasopressinantagonistinpatientshospital-izedforheartfailureTheEVEＲESTClinicalStatusTrialsJ．JAMA2007297121332－1343．2GheorghiadeMKonstamMABurnettJCJretal．Effectsoforaltolvap-taninpatientshospitalizedforworseningheartfailureTheEVEＲESTOutcomeTrialJ．JAMA2007297121319－1331．3BlairJZannadFKonstamMetal．ContinentaldifferencesinclinicalcharacteristicsmanagementandoutcomesinpatientshospitalizedwithworseningheartfailureJ．JAmCollCardio200852201640－1648．4UdelsonJEMcGrewF．Aetal．MulticenterＲandomizedDouble-BlindPlacebo-ControlledStudyontheEffectofOralTolvaptanonLeftVentricularDilationandFunctioninPatientsWithHeartFailureandSystolicDysfunctionJ．JAmCollCardiol200749222151－2159．5UdelsonJ．EOrlandiCOuyangJetal．Acutehemodynamiceffectsoftolvaptanavasop-ressinV2receptorblockerinpatientswithsymptomat-icheartfailureandsystolicdysfunctionJ．JAmCollCardiol200852191540－1545．6FerrerE．TolvaptanforthetreatmentofhyponatremiaandcongestiveheartfailureJ．DrugsTodayBaric20104631632－1671．7GheorghiadeMGattisWAO'ConnorCMetal．Effectsoftolvaptanavasopressinanagonistinpatientshospitalizedwithworseningheartfail-ureJ．JAMA2004291161963－1971．8GheorghiadeNiaziIOuyangJetal．VasopressinV2-receptorblockadewithtolvaptaninpatientswithchronicheartfailureresultsfromadoub-le-blindrandomizedtrialJ．Circulation2003107212690－2696．9GheorghiadeMCottlibeSSUdelsonJEetal．VasopressinV2-receptorblockadewithtolvaptanversusfluidrestrictioninthetreatmentofhy-ponatremiaJ．AmJCardiol20069771064－1067．10PangPKonstamMKrasaHetal．Effectsoftolvaptamondyspnoeare-lieffumtheEVEＲESTtrialsJ．JAmCollCardiol200852201640－1648．11．J．2011285387－389．12．J．2008172160－164．13．J．201093271－272．14MHＲA．DrugSafetyUpdate．Tolvaptanover-rapidincreaseinserumso-diumandriskofseriousneurologicaleventsEB/OL．2012－4－19．2014－01－18··421001【】【】Ｒ543．5【】A【】1674－3296201403B－0178－03VSMC1～3。VSMC。VSMC、VSMC、VSMC2。VSMCVSMC4。VSMC。、。。2354'--2-O-β-DTSG、、、、5～9。TSG。12354．--2-O-β-DTSG101406．39。TSG80℃。、、、。12·871·2014373ChinJofClinicalＲationalDrugUseMarch2014Vol.7No.3B